A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients

被引:69
作者
Badia, X
Podzamczer, D
Garcia, M
López-Lavid, C
Consiglio, E
机构
[1] Univ Barcelona, Inst Salud Publ Cataluna, Barcelona 08907, Spain
[2] Bellvitge Hosp, Dept Infect Dis, Barcelona, Spain
[3] Merck Sharp & Dohme Espana SA, Dept Clin Res, Madrid, Spain
关键词
quality of life; HIV; questionnaire; MOS-HIV; MQOL-HIV; clinical research;
D O I
10.1097/00002030-199909100-00017
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To compare the feasibility, reliability, validity and sensitivity to change of the MOS-HIV and MQOL-HIV in order to determine their suitability for use in clinical research. Methods: Five hundred and fifty-eight HIV-infected patients and 80 healthy blood donors were randomly assigned to receive the MOS-HIV or MQOL-HIV. Test-retest reliability was assessed in 98 clinically stable patients, and responsiveness in 296 patients initiating or switching anti-retroviral treatment. Feasibility was assessed using mean time of administration and percentage of missing responses. Reliability was assessed using Cronbach's alpha and the intraclass correlation coefficient (ICC). Construct validity was assessed by correlating questionnaire scores with EuroQol-5D scores, number of symptoms, CD4 cell count and viral load. The area under the curve (AUC) was used for discrimination between patients and healthy donors, and HRQoL scores were compared across disease stage. Responsiveness was assessed by calculating the standardized effect size (SES). Results: Mean administration time was 16 minutes for both questionnaires. On the MOS-HIV 18.9% patients had missing responses compared with 33.6% on the MQOL-HIV. Cronbach's ct values were higher for MOS-HIV sub-scales (0.78-0.89) than MQOL-HIV sub-scales (0.44-0.82), and neither instrument showed good test-retest reliability (ICC values of 0.24-0.85 for MOS-HIV versus 0.48-0.82 for MQOL-HIV). AUC values for the MOS-HIV were 0.6-0.86, compared with 0.5-0.79 for the MQOL-HIV, and the MOS-HIV had higher correlations with symptoms (r = -0.28 to 0.79) and EuroQol scores (r = 0.4-0.66) than the MQOL-HIV (r = -0.15 to 0.42 and r = -0.11 to 0.59, respectively). Neither instrument discriminated well between disease stages. Eight of 11 MOS-HIV sub-scales and the Mental Health Summary Score were responsive to change (SES, 0.18-0.36), compared with six of 10 MQOL-HIV sub-scales and MQOL Index (SES, 0.16-0.27). Conclusions: Neither instrument demonstrated completely satisfactory psychometric properties for use in clinical research, although the MOS-HIV performed slightly better on feasibility and validity and the MQOL-HIV on test-retest reliability. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:1727 / 1735
页数:9
相关论文
共 47 条
[1]   Quality of life: A dynamic construct [J].
Allison, PJ ;
Locker, D ;
Feine, JS .
SOCIAL SCIENCE & MEDICINE, 1997, 45 (02) :221-230
[2]   Using the EuroQol 5-D in the Catalan general population: feasibility and construct validity [J].
Badia, X ;
Schiaffino, A ;
Alonso, J ;
Herdman, M .
QUALITY OF LIFE RESEARCH, 1998, 7 (04) :311-322
[3]  
*BHIVA GUID COORD, 1997, LANCET, V347, P1086
[4]   EuroQol: The current state of play [J].
Brooks, R .
HEALTH POLICY, 1996, 37 (01) :53-72
[5]   THE RELIABILITY AND VALIDITY OF 2 HIV-SPECIFIC HEALTH-RELATED QUALITY-OF-LIFE MEASURES - A PRELIMINARY-ANALYSIS [J].
BURGESS, A ;
DAYER, M ;
CATALAN, J ;
HAWKINS, D ;
GAZZARD, B .
AIDS, 1993, 7 (07) :1001-1008
[6]   Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease [J].
Cameron, DW ;
Heath-Chiozzi, M ;
Danner, S ;
Cohen, C ;
Kravcik, S ;
Maurath, C ;
Sun, E ;
Henry, D ;
Rode, R ;
Potthoff, A ;
Leonard, J .
LANCET, 1998, 351 (9102) :543-549
[7]   Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :78-86
[8]   Reliability and validity of an HIV-specific health-related quality-of-life measure for use with injecting drug users [J].
Carretero, MD ;
Burgess, AP ;
Soler, P ;
Soler, M ;
Catalan, J .
AIDS, 1996, 10 (14) :1699-1705
[9]   A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease [J].
Cohen, C ;
Revicki, DA ;
Nabulsi, A ;
Sarocco, PW ;
Jiang, P .
AIDS, 1998, 12 (12) :1495-1502
[10]  
Cohen J., 1988, Statistical Power Analysis for the Behavioral Sciences, V2